These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9167130)

  • 1. Mixing insulin lispro and ultralente insulin.
    Bastyr EJ; Holcombe JH; Anderson JH; Clore JN
    Diabetes Care; 1997 Jun; 20(6):1047-8. PubMed ID: 9167130
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of mixing glargine and short-acting insulin analogs on glucose control.
    Kaplan W; Rodriguez LM; Smith OE; Haymond MW; Heptulla RA
    Diabetes Care; 2004 Nov; 27(11):2739-40. PubMed ID: 15505016
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes.
    Rassam AG; Zeise TM; Burge MR; Schade DS
    Diabetes Care; 1999 Jan; 22(1):133-6. PubMed ID: 10333914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro).
    Rabasa-Lhoret R; Bourque J; Ducros F; Chiasson JL
    Diabetes Care; 2001 Apr; 24(4):625-30. PubMed ID: 11315820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin lispro (Humalog), a novel fast-acting insulin analogue: guidelines for its practical use.
    Nobels FR; Hermans MP; De Leeuw I
    Acta Clin Belg; 1999 Oct; 54(5):246-54. PubMed ID: 10555382
    [No Abstract]   [Full Text] [Related]  

  • 8. Basal insulin replacement and use of rapid-acting insulin analogues in patients with type 1 diabetes.
    Zinman B
    Endocr Pract; 2000; 6(1):88-92. PubMed ID: 11419927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes.
    Cengiz E; Tamborlane WV; Martin-Fredericksen M; Dziura J; Weinzimer SA
    Diabetes Care; 2010 May; 33(5):1009-12. PubMed ID: 20150302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.
    Lepore G; Dodesini AR; Nosari I; Trevisan R
    Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625
    [No Abstract]   [Full Text] [Related]  

  • 11. [Flexible intensive insulin therapy: a change in mentalities].
    Penfornis A; Chabroux S; Grimaldi A
    Rev Med Interne; 2008 Nov; 29(11):857-60. PubMed ID: 18387717
    [No Abstract]   [Full Text] [Related]  

  • 12. Updating the insulin lispro file.
    Grossman LD
    CMAJ; 1998 May; 158(9):1132-3. PubMed ID: 9597962
    [No Abstract]   [Full Text] [Related]  

  • 13. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen.
    Mohn A; Strang S; Wernicke-Panten K; Lang AM; Edge JA; Dunger DB
    Diabetes Care; 2000 Apr; 23(4):557-9. PubMed ID: 10857953
    [No Abstract]   [Full Text] [Related]  

  • 14. Vanadyl sulfate does not enhance insulin action in patients with type 1 diabetes.
    Aharon Y; Mevorach M; Shamoon H
    Diabetes Care; 1998 Dec; 21(12):2194-5. PubMed ID: 9839120
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of adolescents with type 1 diabetes mellitus.
    Garg S; Chase HP
    J Pediatr Endocrinol Metab; 2004 May; 17(5):805-6. PubMed ID: 15237718
    [No Abstract]   [Full Text] [Related]  

  • 17. A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes.
    Korsatko S; Glettler K; Olsen KJ; Wutte A; Bock G; Koehler G; Mader JK; Semlitsch B; Pieber TR
    Diabetes Obes Metab; 2013 Mar; 15(3):241-5. PubMed ID: 23013357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients.
    Rave K; Heinemann L; Puhl L; Gudat U; Woodworth JR; Weyer C; Heise T
    Diabetes Care; 1999 May; 22(5):865-6. PubMed ID: 10332707
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimizing glycemic control with insulin glargine.
    Williams JB
    Diabetes Technol Ther; 2003; 5(3):471-3. PubMed ID: 12828834
    [No Abstract]   [Full Text] [Related]  

  • 20. On calculating treatment satisfaction.
    Bradley C
    Diabetes Care; 1999 Oct; 22(10):1760. PubMed ID: 10526762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.